Baxter buys ApaTech; Bosentran study doesn't meet endpoint;

 @FierceBiotech: New Novartis CEO Jimenez scouting for 'bolt-on' buyouts. Article | Follow @FierceBiotech

 @JohnCFierce: Rockwell Medical's conference call starts late. This company is not putting its best foot forward. Follow @JohnCFierce

> Baxter International and ApaTech, a U.K.-based orthobiologic products company, announced a definitive agreement whereby Baxter will acquire all of the outstanding equity of ApaTech for total consideration of up to $330 million. Release

> Actelion today announced the initial results of BUILD-3, a clinical study evaluating the safety and efficacy of bosentan in patients suffering from idiopathic pulmonary fibrosis. Release

> Human Genome Sciences  said on Monday CFO Timothy Barabe is resigning to pursue another opportunity. Report

> Two significant Israelis life sciences holdings companies are becoming one. Clal Biotechnology Industries announced that it will acquire Biomedical Investments for NIS 84 million in cash, shares and warrants. Clal Biotech will pay NIS 28 million, and allot to Biomedical 3 million shares and 1.25 million warrants. Story

> Perrigo Company has signed a definitive purchase agreement to acquire Orion Laboratories for approximately $48 million in cash. Release

And Finally... Dr. Sheldon G. Gilgore, a leader of two major pharmaceutical companies--Pfizer and G.D. Searle--during decades of rapid change in the drug business, died Feb. 12 in his home in Naples, Fla. Report

Suggested Articles

Genor Biopharma banked $160 million from the likes of Hillhouse and Temasek Holdings to advance its clinical-stage autoimmune and cancer programs.

Going from being the CSO of Bristol Myers Squibb to running one of the biggest cancer research organizations in the world is a major career shift.

Hahn made the commitment in a speech that called on the FDA to learn from the crisis to enact lasting policies that accelerate drug development.